Turku, Finland – Researchers at the University of Turku, have uncovered how the new bexmarilimab therapy alters the function of immune cells so that they can infiltrate the tumor in cancer patients who do not respond to any other current therapies. Cancer immunotherapy utilizes the body’s own defense machinery, the...
treatment News
Düsseldorf, Germany – A recent case report from Germany highlights the potential of blinatumomab, a cancer therapy, in treating refractory generalized myasthenia gravis (gMG)— a form of the autoimmune disease that does not respond to standard treatments. Two women with severe, treatment-resistant MG experienced marked clinical improvements following treatment with...
San Antonio, Texas – A promising new cancer therapy also appears extremely potent against one of the world’s most devastating infectious diseases: tuberculosis (TB). Scientists at Texas Biomedical Research Institute (Texas Biomed) found the therapy dramatically reduces TB growth, even for bacteria that are drug-resistant. The findings, reported in the journal...
ATLANTA – Cancer Treatment Centers of America® (CTCA) Atlanta has launched its Women’s Cancer Center, led by an experienced roster of fellowship-trained, board-certified physicians and clinicians with expertise in breast and gynecologic oncology. The center offers comprehensive cancer care – from screenings, diagnostic evaluations and treatment plans to supportive care...
NEEDHAM, Mass. — Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today announced the presentation of updated data from an ongoing phase 1b clinical trial of its herpes simplex virus-1 (HSV-1) replication-competent viral immunotherapy candidate, CAN-3110,...
NEEDHAM, Mass. — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the European Medicines Agency (EMA) has granted Orphan Designation for CAN-2409 (aglatimagene besadenovec) for the treatment of pancreatic cancer. This...
NEEDHAM, Mass. — Candel Therapeutics, Inc., a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CAN-2409, Candel’s most advanced multimodal biological immunotherapy candidate, for the treatment of...
NEEDHAM, Mass. — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced encouraging interim data from its ongoing phase 1b clinical trial of CAN-3110 (linoserpaturev) in recurrent glioblastoma, and a publication in the...
LUND, SWEDEN – Cantargia (STO:CANTA) (Cantargia AB; Nasdaq Stockholm: CANTA) today reported on the progress in the upcoming phase Ib/IIa clinical trial investigating nadunolimab in up to 40 patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). This trial is financed through a grant from the US Department of...
LUND, Sweden – Cantargia (STO:CANTA) (Cantargia AB; Nasdaq Stockholm:CANTA) today reported that after both FDA and IRB review, regulatory approval has been granted to start recruiting patients in a controlled phase IIb trial in metastatic pancreatic cancer (PDAC) investigating nadunolimab as first line combination therapy. The trial is planned to...